May 27, 2022
LOS ANGELES, May 27, 2022 /PRNewswire/ — DxTerity Diagnostics today announced the opening of enrollment in ELEVATE (Empower Lupus Erythematous Patients Via Allowing RemoTe Evaluation), a new observational clinical study for patients with Systemic Lupus Erythematosus (SLE or lupus). The study opening aligns with Lupus Awareness Month (May) and efforts to advance precision medicine and improve the lives of patients living with lupus.
The ELEVATE study (www.theelevatestudy.com) will build upon what was learned from a previous DxTerity study called LIFT. In LIFT, a key biomarker, Type-1 Interferon (IFN-1), was determined to be an important indicator of SLE disease prognosis and high IFN-1 activity was increased in African Americans, Hispanics, Asians, and Native Americans…
Read the full article on PR Newswire.
